Immatics and MDACC have created Immatics US, Inc. to develop multiple next generation adoptive cell therapies for the treatment of cancer


Immatics US, Inc. is developing multiple, next-generation Adoptive Cell Therapies (ACT) for the treatment of cancer. These therapies use human T-cells that have been multiplied outside the body before being infused into a cancer patient, where they recognize and kill tumor cells.

T-cells are a type of white blood cell that plays a central role in the immune system by recognizing antigens, typically presented on the surface of abnormal cells, and triggering an immune response.

Immatics is well positioned to become a global leader in ACT based on its cancer target discovery engine XPRESIDENT®. This platform enables the discovery of ACT targets from amongst the full array of proteins expressed by a cancer cell, including intra-cellular proteins not addressed by antibody and Chimeric Antigen Receptors (CAR) approaches.

Immatics US, Inc. is the only company globally working on three different ACT approaches using multiple proprietary cancer targets. These approaches aim to deliver a step change in the treatment of solid tumors against which current therapies deliver only limited clinical and survival benefits.

Pre-clinical development is well underway and clinical development of the company’s lead ACT is expected to commence in 2016.

Recent Highlighted News